Cytosorbents Corp

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

CTSO$5.80-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)


· · Year ended · · Year ended
· · December 31, · · December 31,
· · 2025 · · 2024
Revenue, net	$37,063	$35,595
Cost of goods sold	10,572	10,708
Gross profit	26,491	24,887
Operating expenses:
Research and development, net of grant income	5,085	7,607
Selling, general and administrative	35,645	33,732
Restructuring	510	—
Total operating expenses	41,240	41,339
Loss from operations	(14,749)	(16,452)
Other income (expense):
Interest expense, net	(2,612)	(1,399)
Gain (loss) on foreign currency transactions	9,321	(4,225)
Loss on abandoned patents	(559)	(334)
Total other income (expense), net	6,150	(5,958)

Loss before benefit from income taxes	(8,599)	(22,410)

Benefit from income taxes	401	1,691

Net loss	$(8,198)	$(20,719)

Basic and diluted net loss per common share	$(0.13)	$(0.38)

Weighted average number of shares of common stock outstanding	62,231,771	54,434,609

Comprehensive loss:
Net loss	$(8,198)	$(20,719)
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax	(7,229)	3,723
Comprehensive loss	$(15,427)	$(16,996)

CONSOLIDATED STATEMENTS OF CHANGES IN

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.